儿科患者复杂感染的优化管理：头孢他啶/阿维巴坦的作用与效用
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.
作者信息
Bassetti Matteo, Peghin Maddalena, Mesini Alessio, Castagnola Elio
机构信息
Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy.
Department of Health Sciences, University of Genoa, Genoa, Italy.
出版信息
Infect Drug Resist. 2020 Jun 12;13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.
Abstract
Antimicrobial resistance poses a substantial threat to global public health. The pursuit of new antibiotics has decreased and very few options have been investigated for the treatment of complicated multidrug-resistant Gram-negative (MDR-GN) infections in adult population and even less in pediatric patients. Ceftazidime-avibactam (CAZ-AVI) is novel cephalosporin/β-lactamase inhibitor (BL-BLI) combination with broad antibacterial spectrum. The aim of this review is to describe the current and future role CAZ-AVI in the pediatric population with suspected or confirmed MDR-GN infections.
摘要
抗菌药物耐药性对全球公共卫生构成了重大威胁。新抗生素的研发投入减少，针对成人复杂多重耐药革兰氏阴性菌（MDR-GN）感染的治疗选择很少被研究，而针对儿科患者的治疗选择更少。头孢他啶-阿维巴坦（CAZ-AVI）是一种新型头孢菌素/β-内酰胺酶抑制剂（BL-BLI）组合，具有广谱抗菌活性。本综述的目的是描述CAZ-AVI在疑似或确诊MDR-GN感染的儿科患者中的当前和未来作用。
相似文献
1
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.儿科患者复杂感染的优化管理：头孢他啶/阿维巴坦的作用与效用
Infect Drug Resist. 2020 Jun 12;13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.
2
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.头孢他啶-阿维巴坦：一种用于治疗耐药革兰氏阴性菌的新型头孢菌素/β-内酰胺酶抑制剂组合
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
3
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.OXA-48 介导的头孢他啶-阿维巴坦耐药与进化权衡有关。
mSphere. 2019 Mar 27;4(2):e00024-19. doi: 10.1128/mSphere.00024-19.
4
Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.阿维巴坦+头孢他啶治疗医院获得性肺炎的药代动力学药物评价
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):331-340. doi: 10.1080/17425255.2018.1434142. Epub 2018 Jan 31.
5
Knowledge, Attitude, and Practice (KAP) Survey on the Management of Multidrug-Resistant Gram-Negative Infections With Innovative Antibiotics: Focus on Ceftazidime-Avibactam.关于使用创新抗生素管理多重耐药革兰氏阴性菌感染的知识、态度和实践（KAP）调查：以头孢他啶-阿维巴坦为重点
Cureus. 2023 May 19;15(5):e39245. doi: 10.7759/cureus.39245. eCollection 2023 May.
6
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.使用头孢他啶/阿维巴坦治疗复杂碳青霉烯类耐药肠杆菌科感染：一项结合分子菌株特征的回顾性研究。
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
7
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.头孢他啶/阿维巴坦：一种用于革兰氏阴性菌感染的新型抗生素。
Consult Pharm. 2015 Dec;30(12):695-705. doi: 10.4140/TCP.n.2015.695.
8
Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.头孢他啶-阿维巴坦对表达联合耐药机制的多重耐药肠杆菌科细菌的活性。
Enferm Infecc Microbiol Clin. 2017 Oct;35(8):499-504. doi: 10.1016/j.eimc.2016.09.013. Epub 2016 Nov 22.
9
Ceftazidime-Avibactam Treatment for Severe Post-Neurosurgical Meningitis and Abscess Caused by Extended-Spectrum β-Lactamase in a Pediatric Patient: A Case Report.头孢他啶-阿维巴坦治疗儿童患者因产超广谱β-内酰胺酶所致严重神经外科术后脑膜炎和脑脓肿：一例报告
Infect Drug Resist. 2023 Mar 30;16:1905-1911. doi: 10.2147/IDR.S403527. eCollection 2023.
10
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.头孢洛扎他唑巴坦和头孢他啶/阿维巴坦：两种新型β-内酰胺/β-内酰胺酶抑制剂复方制剂，用于治疗耐药革兰氏阴性菌感染。
Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14.
引用本文的文献
1
Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.新生儿多重耐药革兰阴性菌败血症：头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦的特殊作用
Medicines (Basel). 2025 Jun 26;12(3):17. doi: 10.3390/medicines12030017.
2
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.朋友还是敌人？应对多重耐药/广泛耐药革兰氏阴性菌的新型抗菌药物：一项系统综述
Front Microbiol. 2024 May 10;15:1385475. doi: 10.3389/fmicb.2024.1385475. eCollection 2024.
3
Carbapenem-resistant Enterobacterales among hospitalized patients in Cape Town, South Africa: clinical and microbiological epidemiology.南非开普敦住院患者中耐碳青霉烯类肠杆菌科细菌：临床和微生物学流行病学
JAC Antimicrob Resist. 2024 Mar 22;6(2):dlae051. doi: 10.1093/jacamr/dlae051. eCollection 2024 Apr.
4
Urinary tract infections in children from the Gulf Cooperation Council countries: a literature review (2011-2022).海湾合作委员会国家儿童尿路感染：文献综述（2011 - 2022年）
Front Pediatr. 2023 Jul 17;11:1163103. doi: 10.3389/fped.2023.1163103. eCollection 2023.
5
Thymol-Decorated Gold Nanoparticles for Curing Clinical Infections Caused by Bacteria Resistant to Last-Resort Antibiotics.百里香酚修饰的金纳米颗粒治愈对抗生素耐药的临床细菌感染。
mSphere. 2023 Jun 22;8(3):e0054922. doi: 10.1128/msphere.00549-22. Epub 2023 Apr 5.
6
Epidemiology and clinical characteristics of infection/colonization due to carbapenemase-producing Enterobacterales in neonatal patients.产碳青霉烯酶肠杆菌科在新生儿患者中感染/定植的流行病学和临床特征。
BMC Microbiol. 2022 Jul 12;22(1):177. doi: 10.1186/s12866-022-02585-z.
7
Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.静脉注射头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染的极早产儿：两例报告
J Pediatr Pharmacol Ther. 2022;27(2):192-197. doi: 10.5863/1551-6776-27.2.192. Epub 2022 Feb 9.
8
Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality.接受化疗或造血干细胞移植的儿科患者的耐抗生素血流感染：与耐药性发展、重症监护入院和死亡率相关的因素
Antibiotics (Basel). 2021 Mar 5;10(3):266. doi: 10.3390/antibiotics10030266.
本文引用的文献
1
Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.头孢他啶-阿维巴坦治疗 3 个月至＜18 岁复杂性尿路感染儿童的安全性和疗效：一项 2 期随机对照试验的结果。
Pediatr Infect Dis J. 2019 Sep;38(9):920-928. doi: 10.1097/INF.0000000000002395.
2
Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.头孢他啶-阿维巴坦加甲硝唑治疗 3 月龄至<18 岁复杂性腹腔感染儿童的安全性和疗效：一项 2 期随机对照试验的结果。
Pediatr Infect Dis J. 2019 Aug;38(8):816-824. doi: 10.1097/INF.0000000000002392.
3
Ceftazidine-avibactam salvage therapy in newborn with KPC-producing Klebsiella pneumoniae invasive infections.头孢他啶-阿维巴坦挽救治疗产KPC肺炎克雷伯菌侵袭性感染的新生儿。
Minerva Anestesiol. 2019 Jul;85(7):804-805. doi: 10.23736/S0375-9393.19.13521-3.
4
Fosfomycin in the pediatric setting: Evidence and potential indications.儿科环境中的磷霉素：证据与潜在适应症。
Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):55-61.
5
Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.头孢他啶-阿维巴坦联合磷霉素：一种治疗多重耐药铜绿假单胞菌的新策略。
J Infect Dis. 2019 Jul 19;220(4):666-676. doi: 10.1093/infdis/jiz149.
6
Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance.儿科和新生儿脓毒症的未来挑战：新出现的病原体与抗菌药物耐药性
J Pediatr Intensive Care. 2019 Mar;8(1):17-24. doi: 10.1055/s-0038-1677535. Epub 2019 Jan 17.
7
Treatment of Infections Due to MDR Gram-Negative Bacteria.多重耐药革兰氏阴性菌感染的治疗
Front Med (Lausanne). 2019 Apr 16;6:74. doi: 10.3389/fmed.2019.00074. eCollection 2019.
8
Management of carbapenem-resistant Enterobacteriaceae infections.碳青霉烯类耐药肠杆菌科感染的管理。
Clin Microbiol Infect. 2019 Aug;25(8):943-950. doi: 10.1016/j.cmi.2019.04.013. Epub 2019 Apr 18.
9
Potential pitfalls in LC-MS/MS quantification of colistin for therapeutic drug monitoring of patients treated with colistimethate.多粘菌素 E 治疗药物监测中 LC-MS/MS 定量检测多粘菌素的潜在陷阱。
J Pharm Biomed Anal. 2019 Jun 5;170:193-195. doi: 10.1016/j.jpba.2019.03.023. Epub 2019 Mar 14.
10
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring and Investigated Using Time-Kill and Disk Approximation Assays.头孢他啶-阿维巴坦与美罗培南对泛耐药、产碳青霉烯酶、被研究使用时间杀伤和药敏纸片近似法测定的菌株的协同作用。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02367-18. Print 2019 May.
Zotero 插件